[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=6975e55cd9437fc3e5e1e5a6d8f1494ab3aee3a9689d54b09468b476623651fb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755707460,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136453832,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=6975e55cd9437fc3e5e1e5a6d8f1494ab3aee3a9689d54b09468b476623651fb"
    }
  },
  {
    "ts": null,
    "headline": "Record Quarter for Gubra, but Revised Outlook for the CRO Business",
    "summary": "HORSHOLM, DENMARK / ACCESS Newswire / August 20, 2025 / Revenue and earnings for Gubra Group (CPH:GUBRA) have been record-high in the second quarter of 2025 driven by the outlicensing deal with AbbVie in our Discovery & Partnerships business. While ...",
    "url": "https://finnhub.io/api/news?id=858ca9f6eb42aa072497dbc74b1adfa7b6dd2860997faf5e87f7432d960b2f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755704700,
      "headline": "Record Quarter for Gubra, but Revised Outlook for the CRO Business",
      "id": 136450330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "HORSHOLM, DENMARK / ACCESS Newswire / August 20, 2025 / Revenue and earnings for Gubra Group (CPH:GUBRA) have been record-high in the second quarter of 2025 driven by the outlicensing deal with AbbVie in our Discovery & Partnerships business. While ...",
      "url": "https://finnhub.io/api/news?id=858ca9f6eb42aa072497dbc74b1adfa7b6dd2860997faf5e87f7432d960b2f07"
    }
  },
  {
    "ts": null,
    "headline": "Does Cobenfy Have the Potential to Become a Top Drug for BMY?",
    "summary": "Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.",
    "url": "https://finnhub.io/api/news?id=c5a68468a846f104f35a0af88499def4e26c28d4cb90985c4ab028887ab577e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755697920,
      "headline": "Does Cobenfy Have the Potential to Become a Top Drug for BMY?",
      "id": 136437475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.",
      "url": "https://finnhub.io/api/news?id=c5a68468a846f104f35a0af88499def4e26c28d4cb90985c4ab028887ab577e4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?",
    "summary": "AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.",
    "url": "https://finnhub.io/api/news?id=df7269fe38944b05cba71ec4287acb655269ff61fcf3a3155df8bfe7e97031b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755697200,
      "headline": "AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?",
      "id": 136437354,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.",
      "url": "https://finnhub.io/api/news?id=df7269fe38944b05cba71ec4287acb655269ff61fcf3a3155df8bfe7e97031b2"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
    "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
    "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755663369,
      "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
      "id": 136435370,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291269124/image_1291269124.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
      "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a"
    }
  },
  {
    "ts": null,
    "headline": "Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
    "url": "https://finnhub.io/api/news?id=68cef88636aaa7fc0cd9dfec94726e6c9ebba7d704bf8df676a48599fc87c1fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755660994,
      "headline": "Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
      "id": 136437477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.",
      "url": "https://finnhub.io/api/news?id=68cef88636aaa7fc0cd9dfec94726e6c9ebba7d704bf8df676a48599fc87c1fb"
    }
  }
]